Drugs / Kanamycin
Kanamycin
also known as
KAN · Kanamicina · Kanamycin monosulphate · KANAMYCIN SULFATE · Kanamycin sulfate monohydrate · Kanamycine · Kanamycins · Klebcil
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | KANTREX | — | 1973-02-13 | fda.gov ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02128308 | Nov → Dec 2013 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00816426 | Dec 2008 → Aug 2014 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02409290 | Mar 2016 → May 2022 | multidrug-resistant tuberculosis | IUATLD, Inc | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT03237182 | Jun 2017 → Dec 2022 | multidrug-resistant tuberculosis | Centre for the AIDS Programme of Research in South Africa | Terminated | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2/3 | NCT02454205 Comparator | Nov 2015 → Dec 2020 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis | University of Cape Town | Completed | Met primary |
| Phase 3 | NCT02975570 Comparator | Aug 2017 → Aug 2021 | multidrug-resistant tuberculosis | Boston University | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT00508690 Comparator | Sep 2007 → Dec 2011 | colorectal neoplasm | Japan Multinational Trial Organization | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kanamycin | “anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS],...” NCT02365623 ↗8“a parenteral agent (typically amikacin or kanamycin)” NCT02975570 ↗ “capreomycin, kanamycin, streptomycin, ethionamide” NCT03237182 ↗ “Kanamycin” NCT02099240 ↗ |
| Known as | KAN | “kanamycin [KM, KAN]” NCT02365623 ↗ |
| Known as | Kanamicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1384 ↗ |
| Known as | Kanamycin monosulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1384 ↗ |
| Known as | KANAMYCIN SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1384 ↗ |
| Known as | Kanamycin sulfate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1384 ↗ |
| Known as | Kanamycine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1384 ↗ |
| Known as | Kanamycins | ChEMBL registry synonym — accepted as the source's own label CHEMBL1384 ↗ |
| Known as | Klebcil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1384 ↗ |
| Modality | Small molecule | — CHEMBL1384 ↗ |
| Route | Oral | “oral kanamycin(1g)” NCT00508690 ↗ |